Biotech Values

[jq1234]

If it is just comparable to Zytiga plus prednisone, I don't think MDV3100 automatically becomes SOC. If you base on topline efficacy data alone, it's too early to say. I had discussion previously the large number difference between placebo arms could imply there are differences in enrolled patient population to explain the mOS difference.